Statera Biopharma (STAB) Short Interest Ratio & Short Volume

Short interest is the volume of Statera Biopharma shares that have been sold short but have not yet been covered or closed out. As of December 30th, investors have sold 774,500 shares of STAB short. 1.71% of Statera Biopharma's shares are currently sold short. Learn More on Statera Biopharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.71% of Statera Biopharma's floating shares are currently sold short.

Statera Biopharma saw a decrease in short interest in December. As of December 30th, there was short interest totaling 774,500 shares, a decrease of 38.0% from the previous total of 1,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Statera Biopharma currently has issued a total of 54,662,000 shares. Some of Statera Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Statera Biopharma currently has a public float of 45,330,000 shares.

1.71% of Statera Biopharma's shares are currently sold short. Here is how the short interest of companies compare to Statera Biopharma: Bruush Oral Care Inc. (62.06%), Context Therapeutics Inc. (0.08%), Grifols, S.A. (2.32%), LAVA Therapeutics (1.50%), Mainz Biomed (2.34%), Pharvaris (0.10%), Athersys, Inc. (12.51%), TransCode Therapeutics, Inc. (0.61%), Galmed Pharmaceuticals Ltd. (1.10%), Bellerophon Therapeutics, Inc. (0.55%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.31 billion), T. Rowe Price Group, Inc. ($2.13 billion), TC Energy Co. ($2.13 billion), Paramount Global ($1.50 billion), Coinbase Global, Inc. ($1.48 billion), Etsy, Inc. ($1.48 billion), PG&E Co. ($1.47 billion), Old Dominion Freight Line, Inc. ($1.46 billion), United Rentals, Inc. ($1.35 billion), and Voya Financial, Inc. ($1.32 billion). View all of the most shorted stocks.

Short selling STAB is an investing strategy that aims to generate trading profit from Statera Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Statera Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of STAB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including STAB, twice per month. The most recent reporting period available is December, 30 2022.